CJC-1295 no DAC & Ipamorelin vs Sermorelin: Protocol Comparison
Primary Mechanism GHRH receptor agonism only Dual-pathway: GHRH receptor + ghrelin receptor (GHS-R1a) The combination's dual-pathway activation delivers synergistic GH pulse amplitude that single-pathway protocols can't match Effective Half-Life 7–10 minutes C
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHRH receptor agonism only
- Dual-pathway: GHRH receptor + ghrelin receptor (GHS-R1a)
- The combination's dual-pathway activation delivers synergistic GH pulse amplitude that single-pathway protocols can't match
- Effective Half-Life
- 7–10 minutes
- CJC-1295 no DAC: ~30 min; Ipamorelin: ~2 hours
- Extended duration translates to fewer daily injections and more sustained IGF-1 elevation
- Typical Dosing Frequency
- 2–3 injections daily
- Once daily (typically evening administration)
- Once-daily protocols reduce handling complexity and contamination risk
- Peak GH Pulse Amplitude
- Baseline to 2–4× elevation
- Baseline to 3–6× elevation (synergistic effect)
- Higher peak amplitude correlates with greater downstream IGF-1 response
- IGF-1 Response Timeline
- Measurable increase within 2–3 weeks
- Measurable increase within 10–14 days
- Slightly faster IGF-1 elevation with combination, though both require 2+ weeks for meaningful changes
- Side Effect Frequency
- Mild: flushing, injection-site reactions, occasional headaches
- Equivalent to Sermorelin despite higher GH output
- Ipamorelin's selectivity prevents the cortisol/prolactin elevation seen with older ghrelin mimetics
- Receptor Desensitisation Risk
- Low (mimics natural pulsatility)
- Low (dual pathways reduce single-receptor overstimulation)
- Both protocols preserve natural feedback loops better than continuous-release formulations
- Cost per Week (Typical)
- Moderate (higher per-injection cost, more frequent dosing)
- Moderate to high (lower injection frequency offsets per-dose cost)
- Total weekly cost is comparable when factoring injection frequency